FDA Evaluates Potential Link Between Bisphosphonate Class And Atrial Fibrillation
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent journal articles on the osteoporosis products’ association with atrial fibrillation spark an “early safety communication" from the agency.
You may also be interested in...
FDA Warns About Musculoskeletal Pain With Bisphosphonate Use
Agency asks physicians to consider discontinuing treatment despite lack of causal link to pain.
FDA Warns About Musculoskeletal Pain With Bisphosphonate Use
Agency asks physicians to consider discontinuing treatment despite lack of causal link to pain.
Teva Gains ANDA Approval For Generic Actonel
Firm awaits Delaware federal court decision on pending litigation with Actonel marketer Procter & Gamble.